CMPX
Compass Therapeutics Inc.
NASDAQ: CMPX · HEALTHCARE · BIOTECHNOLOGY
$1.83
-4.23% today
Updated 2026-06-05
Market cap
$428.61M
P/E ratio
—
P/S ratio
269.28x
EPS (TTM)
$-0.40
Dividend yield
—
52W range
$2 – $7
Volume
8.9M
Compass Therapeutics Inc. (CMPX) Insider transactions
Net insider activity
Net buying (12,114,368 shares)
Buy transactions
84
Sell transactions
16
All transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-04-29 | LERNER, NEIL | Chief Accounting Officer | Buy | 15,000 | $1.89 | $28350.00 |
| 2026-04-29 | ANDERMAN, JONATHAN | General Counsel | Buy | 25,000 | $1.89 | $47250.00 |
| 2026-02-08 | SCHUETZ, THOMAS J. | Director, CHIEF EXECUTIVE OFFICER | Sale | 36,687 | $6.52 | $239199.24 |
| 2026-01-09 | SCHUETZ, THOMAS J. | Director, CHIEF EXECUTIVE OFFICER | Sale | 46,777 | $5.35 | $250256.95 |
| 2026-01-02 | SIRARD, CYNTHIA | Chief Medical Officer | Buy | 1,000,000 | — | — |
| 2026-01-02 | SHIN, BARRY | CFO | Buy | 670,000 | — | — |
| 2026-01-02 | SHIN, BARRY | CFO | Buy | 125,000 | $5.17 | $646250.00 |
| 2026-01-02 | SCHUETZ, THOMAS J. | Director, CEO | Buy | 2,000,000 | — | — |
| 2026-01-02 | SCHUETZ, THOMAS J. | Director, CEO | Buy | 250,000 | $5.17 | $1.29M |
| 2026-01-02 | PRASAD, ARJUN | Chief Commercial Officer | Buy | 1,000,000 | — | — |
| 2026-01-02 | LINDAHL, RICHARD S | Director | Buy | 90,000 | — | — |
| 2026-01-02 | LERNER, NEIL | Chief Accounting Officer | Buy | 435,000 | — | — |
| 2026-01-02 | LERNER, NEIL | Chief Accounting Officer | Buy | 62,500 | $5.17 | $323125.00 |
| 2026-01-02 | GRAY, MARY ANN | Director | Buy | 90,000 | — | — |
| 2026-01-02 | GORDON, CARL L | Director | Buy | 90,000 | — | — |
| 2026-01-02 | FERNEAU, PHILIP | Director | Buy | 90,000 | — | — |
| 2026-01-02 | CHINIARA, ELLEN | Director | Buy | 90,000 | — | — |
| 2026-01-02 | BOYLAN, JAMES P | Director | Buy | 90,000 | — | — |
| 2026-01-02 | ANDERMAN, JONATHAN | General Counsel | Buy | 720,000 | — | — |
| 2026-01-02 | ANDERMAN, JONATHAN | General Counsel | Buy | 150,000 | $5.17 | $775500.00 |
| 2025-11-16 | SCHUETZ, THOMAS J. | Director, CHIEF EXECUTIVE OFFICER | Sale | 44,025 | $4.83 | $212640.75 |
| 2025-05-27 | SCHUETZ, THOMAS J. | Director, CHIEF EXECUTIVE OFFICER | Buy | 10,000 | $2.11 | $21100.00 |
| 2025-04-09 | ORBIMED, ADVISORS LLC | Director, 10% Owner | Sale | 3,571,428 | $1.59 | $5.68M |
| 2025-04-09 | GORDON, CARL L | Director, 10% Owner | Sale | 3,571,428 | $1.59 | $5.68M |
| 2025-04-07 | LERNER, NEIL | CHIEF ACCOUNTING OFFICER | Buy | 20,000 | $1.42 | $28400.00 |
| 2025-04-07 | ANDERMAN, JONATHAN | Gen Counsel & Corporate Sec | Buy | 20,000 | $1.54 | $30800.00 |
| 2025-02-11 | SHIN, BARRY | CFO | Buy | 250,000 | — | — |
| 2025-02-11 | SCHUETZ, THOMAS J. | Director, CHIEF EXECUTIVE OFFICER | Buy | 1,500,000 | — | — |
| 2025-02-11 | LINDAHL, RICHARD S | Director | Buy | 40,000 | — | — |
| 2025-02-11 | LERNER, NEIL | SVP, CAO | Buy | 200,000 | — | — |
| 2025-02-11 | GRAY, MARY ANN | Director | Buy | 40,000 | — | — |
| 2025-02-11 | GORDON, CARL L | Director, 10% Owner | Buy | 40,000 | — | — |
| 2025-02-11 | FERNEAU, PHILIP | Director | Buy | 40,000 | — | — |
| 2025-02-11 | CHINIARA, ELLEN | Director | Buy | 40,000 | — | — |
| 2025-02-11 | BOYLAN, JAMES P | Director | Buy | 40,000 | — | — |
| 2025-02-11 | ANDERMAN, JONATHAN | Sr VP, Gen Counsel & Corp Sec | Buy | 280,000 | — | — |
| 2025-02-08 | SCHUETZ, THOMAS J. | Director, CEO | Sale | 41,687 | $3.50 | $145904.50 |
| 2025-01-09 | SCHUETZ, THOMAS J. | Director, CEO | Sale | 58,054 | $1.86 | $107980.44 |
| 2024-12-09 | SHIN, BARRY | CFO | Buy | 400,000 | — | — |
| 2024-12-09 | SHIN, BARRY | CFO | Buy | 400,000 | $1.65 | $660000.00 |
| 2024-08-13 | ANDERMAN, JONATHAN | Sr VP, Gen Counsel & Corp Sec | Buy | 300,000 | — | — |
| 2024-03-08 | BOYLAN, JAMES P | Director | Buy | 40,000 | — | — |
| 2024-02-09 | LINDAHL, RICHARD S | Director | Buy | 40,000 | — | — |
| 2024-02-09 | GRAY, MARY ANN | Director | Buy | 40,000 | — | — |
| 2024-02-09 | GORDON, CARL L | Director, 10% Owner | Buy | 40,000 | — | — |
| 2024-02-09 | FERNEAU, PHILIP | Director | Buy | 40,000 | — | — |
| 2024-02-09 | CHINIARA, ELLEN | Director | Buy | 40,000 | — | — |
| 2024-02-08 | SCHUETZ, THOMAS J. | Director, PRESIDENT | Sale | 44,782 | $1.45 | $64933.90 |
| 2024-02-08 | BISKER-LEIB, VERED | Director, CHIEF EXECUTIVE OFFICER | Sale | 49,198 | $1.45 | $71337.10 |
| 2024-01-09 | SCHUETZ, THOMAS J. | Director, President of R&D | Buy | 637,500 | — | — |
| 2024-01-09 | SCHUETZ, THOMAS J. | Director, President of R&D | Buy | 637,500 | $1.93 | $1.23M |
| 2024-01-09 | BISKER-LEIB, VERED | Director, Chief Executive Officer | Buy | 1,753,125 | — | — |
| 2024-01-09 | BISKER-LEIB, VERED | Director, Chief Executive Officer | Buy | 1,753,125 | $1.93 | $3.38M |
| 2023-11-17 | SCHUETZ, THOMAS J. | Director, CHIEF EXECUTIVE OFFICER | Sale | 44,025 | $1.50 | $66037.50 |
| 2023-11-17 | BISKER-LEIB, VERED | Chief Operating Officer | Sale | 64,415 | $1.50 | $96622.50 |
| 2023-04-21 | LINDAHL, RICHARD S | Director | Buy | 50,000 | — | — |
| 2023-03-10 | SCHUETZ, THOMAS J. | Director, CHIEF EXECUTIVE OFFICER | Buy | 10,000 | $3.37 | $33700.00 |
| 2023-02-27 | SCHUETZ, THOMAS J. | Director, CHIEF EXECUTIVE OFFICER | Buy | 20,000 | $3.98 | $79600.00 |
| 2023-02-15 | SCHUETZ, THOMAS J. | Director, CHIEF EXECUTIVE OFFICER | Buy | 20,000 | $3.86 | $77200.00 |
| 2023-02-08 | WURZER, DAVID M | Director | Buy | 50,000 | — | — |
| 2023-02-08 | SCHUETZ, THOMAS J. | Director, CHIEF EXECUTIVE OFFICER | Buy | 700,000 | — | — |
| 2023-02-08 | SCHUETZ, THOMAS J. | Director, CHIEF EXECUTIVE OFFICER | Buy | 500,000 | — | — |
| 2023-02-08 | GRAY, MARY ANN | Director | Buy | 40,000 | — | — |
| 2023-02-08 | GORDON, CARL L | Director, 10% Owner | Buy | 60,000 | — | — |
| 2023-02-08 | FERNEAU, PHILIP | Director | Buy | 50,000 | — | — |
| 2023-02-08 | CHINIARA, ELLEN | Director | Buy | 40,000 | — | — |
| 2023-02-08 | BISKER-LEIB, VERED | Chief Operating Officer | Buy | 600,000 | — | — |
| 2023-02-08 | BISKER-LEIB, VERED | Chief Operating Officer | Buy | 400,000 | — | — |
| 2023-01-31 | SCHUETZ, THOMAS J. | Director, CHIEF EXECUTIVE OFFICER | Buy | 20,000 | $4.05 | $81000.00 |
| 2023-01-24 | SCHUETZ, THOMAS J. | Director, CHIEF EXECUTIVE OFFICER | Buy | 20,000 | $4.19 | $83800.00 |
| 2022-11-25 | BISKER-LEIB, VERED | Chief Operating Officer | Sale | 2 | $4.36 | $8.72 |
| 2022-11-23 | BISKER-LEIB, VERED | Chief Operating Officer | Sale | 9,569 | $4.30 | $41146.70 |
| 2022-11-22 | BISKER-LEIB, VERED | Chief Operating Officer | Sale | 14,929 | $4.19 | $62552.51 |
| 2022-11-21 | BISKER-LEIB, VERED | Chief Operating Officer | Sale | 16,035 | $4.34 | $69591.90 |
| 2022-11-18 | BISKER-LEIB, VERED | Chief Operating Officer | Sale | 6,226 | $4.40 | $27394.40 |
| 2022-11-08 | ORBIMED, ADVISORS LLC | Director, 10% Owner | Buy | 402,000 | $3.21 | $1.29M |
| 2022-11-08 | GORDON, CARL L | Director, 10% Owner | Buy | 402,000 | $3.21 | $1.29M |
| 2022-09-28 | SCHUETZ, THOMAS J. | Director, CHIEF EXECUTIVE OFFICER | Buy | 10,000 | $2.32 | $23200.00 |
| 2022-09-26 | SCHUETZ, THOMAS J. | Director, CHIEF EXECUTIVE OFFICER | Buy | 15,000 | $2.27 | $34050.00 |
| 2022-09-07 | SCHUETZ, THOMAS J. | Director, CHIEF EXECUTIVE OFFICER | Buy | 15,000 | $3.03 | $45450.00 |
| 2022-09-01 | SCHUETZ, THOMAS J. | Director, CHIEF EXECUTIVE OFFICER | Buy | 15,000 | $2.83 | $42450.00 |
| 2022-08-17 | SCHUETZ, THOMAS J. | Director, CHIEF EXECUTIVE OFFICER | Buy | 15,000 | $3.05 | $45750.00 |
| 2022-08-10 | SCHUETZ, THOMAS J. | Director, CHIEF EXECUTIVE OFFICER | Buy | 15,000 | $2.64 | $39600.00 |
| 2022-08-01 | SCHUETZ, THOMAS J. | Director, CHIEF EXECUTIVE OFFICER | Buy | 15,000 | $2.58 | $38700.00 |
| 2022-06-21 | SCHUETZ, THOMAS J. | Director, CHIEF EXECUTIVE OFFICER | Buy | 20,000 | $2.80 | $56000.00 |
| 2022-06-16 | SCHUETZ, THOMAS J. | Director, CHIEF EXECUTIVE OFFICER | Buy | 20,000 | $2.34 | $46800.00 |
| 2022-06-13 | SCHUETZ, THOMAS J. | Director, CHIEF EXECUTIVE OFFICER | Buy | 30,000 | $2.29 | $68700.00 |
| 2022-06-06 | SCHUETZ, THOMAS J. | Director, CHIEF EXECUTIVE OFFICER | Buy | 30,000 | $2.83 | $84900.00 |
| 2022-06-01 | SCHUETZ, THOMAS J. | Director, CHIEF EXECUTIVE OFFICER | Buy | 20,000 | $3.03 | $60600.00 |
| 2022-05-26 | SCHUETZ, THOMAS J. | Director, CHIEF EXECUTIVE OFFICER | Buy | 20,000 | $3.04 | $60800.00 |
| 2022-05-23 | SCHUETZ, THOMAS J. | Director, CHIEF EXECUTIVE OFFICER | Buy | 18,355 | $2.72 | $49925.60 |
| 2022-05-17 | SCHUETZ, THOMAS J. | Director, CHIEF EXECUTIVE OFFICER | Buy | 20,215 | $2.47 | $49931.05 |
| 2022-05-13 | ORBIMED, ADVISORS LLC | Director, 10% Owner | Buy | 30,722 | $2.49 | $76497.78 |
| 2022-05-13 | GORDON, CARL L | Director, 10% Owner | Buy | 30,722 | $2.49 | $76497.78 |
| 2022-05-12 | ORBIMED, ADVISORS LLC | Director, 10% Owner | Buy | 97,094 | $2.35 | $228170.90 |
| 2022-05-12 | GORDON, CARL L | Director, 10% Owner | Buy | 97,094 | $2.35 | $228170.90 |
| 2022-05-11 | ORBIMED, ADVISORS LLC | Director, 10% Owner | Buy | 64,700 | $1.79 | $115813.00 |
| 2022-05-11 | GORDON, CARL L | Director, 10% Owner | Buy | 64,700 | $1.79 | $115813.00 |
| 2022-05-10 | SCHUETZ, THOMAS J. | Director, CHIEF EXECUTIVE OFFICER | Buy | 27,836 | $1.80 | $50104.80 |
| 2022-05-10 | ORBIMED, ADVISORS LLC | Director, 10% Owner | Buy | 24,447 | $1.60 | $39115.20 |
Frequently asked questions
Are CMPX insiders buying or selling?
Over the transactions on record, CMPX insiders have been net buyers, with about $12.81M in stock sold across 16 sales, against 42 open-market purchases.
Does insider selling at CMPX mean the stock will fall?
Not by itself. Most executive selling is pre-scheduled through 10b5-1 plans filed months in advance, and insiders sell for diversification, taxes, and liquidity far more often than out of any view on the price. Insider buying is the stronger signal, especially when several insiders buy around the same time, because there is usually only one reason to put personal cash into the stock.
Which CMPX insiders are selling the most?
Recent selling is concentrated in a few names. ORBIMED, ADVISORS LLC accounts for the largest share on record, with about $5.68M sold. Selling by one or two individuals matters less than broad selling across the whole leadership team, which is the pattern worth watching.